[go: up one dir, main page]

Pramanik, 2017 - Google Patents

Cortical hyperactivity beyond immune attack: pivotal role of TNF-alpha in early Multiple Sclerosis

Pramanik, 2017

View PDF
Document ID
18334001400138913959
Author
Pramanik G
Publication year

External Links

Snippet

The central nervous system (CNS) is the primary target in both multiple sclerosis (MS) and the animal model of experimental autoimmune encephalomyelitis (EAE). The disease is mainly driven by infiltrating myelin specific T cells that are peripherally activated by antigen …
Continue reading at openscience.ub.uni-mainz.de (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Guo et al. Preservation of vision after CaMKII-mediated protection of retinal ganglion cells
Li et al. Delayed microglial depletion after spinal cord injury reduces chronic inflammation and neurodegeneration in the brain and improves neurological recovery in male mice
Cristiano et al. Neutralization of IL‐17 rescues amyloid‐β‐induced neuroinflammation and memory impairment
Wang et al. Altered mGluR5-Homer scaffolds and corticostriatal connectivity in a Shank3 complete knockout model of autism
Calabrese et al. Exploring the origins of grey matter damage in multiple sclerosis
Peterson et al. Complement protein C1q modulates neurite outgrowth in vitro and spinal cord axon regeneration in vivo
Yandamuri et al. Imaging axonal degeneration and repair in preclinical animal models of multiple sclerosis
Lin et al. Environmental enrichment implies GAT-1 as a potential therapeutic target for stroke recovery
US20140107152A1 (en) Sensory receptors for chronic fatigue and pain and uses
Masala et al. Targeting aberrant dendritic integration to treat cognitive comorbidities of epilepsy
Zhai et al. Blocking GluR2–GAPDH ameliorates experimental autoimmune encephalomyelitis
Cui et al. Altered pain sensitivity in 5× familial Alzheimer disease mice is associated with dendritic spine loss in anterior cingulate cortex pyramidal neurons
Plachez et al. Amyloid deposition and dendritic complexity of Corticocortical projection cells in five familial Alzheimer's disease mouse
Chai et al. Legumain knockout improved cognitive impairment via reducing neuroinflammation in right unilateral common carotid artery occlusion mice
US20170326356A1 (en) Methods for treating psychiatric disorders
Ahmed et al. Pro-inflammatory cytokine GM-CSF improves learning/memory and brain pathology in Dp16 down syndrome mice and improves learning/memory in wild-type mice
Pramanik Cortical hyperactivity beyond immune attack: pivotal role of TNF-alpha in early Multiple Sclerosis
Sung et al. P45 forms a complex with FADD and promotes neuronal cell survival following spinal cord injury
Bendova Impact of sensory cortex dysfunction on sensory perception
Chahin Traumatic brain injury
Chahin Traumatic brain injury: a binding condition in search of solutions
dos Santos Chemelo et al. Potential effects of induced focal ischemia in the motor cortex of rats undergoing experimental periodontitis
Fish Age Bias in Zebrafish Models of Epilepsy: What Can We Learn From
Mustafa Blocking Brain Tumor Necrosis Factor to Alleviate Persistent Inflammatory Pain
Adedipe The role of astrocytes in the effects of early-life stress on lateral amygdala-dependent behaviour